Skip to content

US · GNLX · BIOTECHNOLOGY

Genelux Corporation (GNLX) intrinsic value and stock valuation

$2.17as of 2026-11-21 · Mkt cap 119.28M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Genelux Corporation DCF and intrinsic value

InvestorsCraft values GNLX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from GNLX’s statements →

Genelux Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Westlake Village, CA 91361 genelux.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$10K
20192025
Net income
-$-32.15M
20192025
Free cash flow
-$-26.37M
20192025
Total equity
$11.5M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$10K$10K$170K$11.1M$0.00
Operating income-$-33.21M-$-31.7M-$-24.16M-$-3.01M-$-14.61M
Net income-$-32.15M-$-29.87M-$-28.3M-$-5.21M-$-17.8M
EPSd-$-864.71K-$-949.76K-$-1.16M-$-212.22K-$-753.6K
Operating cash flow-$-25.27M-$-21.23M-$-20.27M-$-3.57M-$-6.58M
Capital expenditure-$-1.1M-$-380K-$-1.02M-$-50K$0.00
Free cash flow-$-26.37M-$-21.61M-$-21.3M-$-3.62M-$-6.58M
Total assets$19M$34.7M$27.9M$5.53M$8.13M
Total debt$1.69M$1.87M$2.52M$26.4M$25.3M
Net debt-$-3.65M-$-6.7M-$-6.9M$26M$20.8M
Total equity$11.5M$26.3M$19.5M-$-35.78M-$-33.11M
Cash and short-term investments$14.6M$30.9M$23.2M$400K$4.5M
Income statement
20252024202320222021
Revenue$10K$10K$170K$11.1M$0.00
Cost of revenue$570K$900K$1.02M$970K$900K
Gross profit-$-570K-$-900K-$-850K$10.1M-$-900K
Research and development expenses$19.9M$19M$12.8M$9.08M$6.32M
Selling, general and administrative expenses$13.4M$12.7M$11.6M$5M$8.29M
Other expenses-$-570K-$-900K-$-1.02M-$-970K-$-900K
Operating expenses$32.7M$30.8M$23.3M$13.1M$13.7M
Cost and expenses$33.2M$31.7M$24.3M$14.1M$14.6M
Interest income$1.07M$1.46M$240K$0.00$0.00
Interest expense$0.00$0.00$3.97M$1.41M$1.81M
Depreciation and amortization$570K$900K$1.02M$970K$900K
Ebitda-$-31.57M-$-28.97M-$-26.46M-$-1.73M-$-13.67M
Operating income-$-33.21M-$-31.7M-$-24.16M-$-3.01M-$-14.61M
Total other income/expenses, net$1.07M$1.83M-$-4.13M-$-1.09M-$-1.76M
Income before tax-$-32.15M-$-29.87M-$-28.3M-$-4.11M-$-16.38M
Income tax expense$0.00$0.00$0.00$1.1M$0.00
Net income-$-32.15M-$-29.87M-$-28.3M-$-5.21M-$-17.8M
Weighted average shares outstanding$37.2M$31.5M$24.4M$24.6M$23.6M
Weighted average diluted shares outstanding$37.2M$31.5M$24.4M$24.6M$23.6M
Balance sheet
20252024202320222021
Cash and short-term investments$14.6M$30.9M$23.2M$400K$4.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$15.1M$31.6M$24.2M$1.89M$5.82M
Property, plant and equipment, net$3.75M$3.08M$3.6M$1.98M$2.21M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.9M$3.17M$3.69M$3.64M$2.3M
Total assets$19M$34.7M$27.9M$5.53M$8.13M
Accounts payable$4.36M$5.57M$3.78M$6.78M$4.46M
Short-term debt$430K$330K$1.31M$16.7M$6.56M
Deferred revenue$0.00$0.00$0.00$170K$4.5M
Total current liabilities$6.22M$6.9M$6.55M$31.6M$22.5M
Long-term debt$1.26M$1.54M$1.87M$9.69M$18.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.26M$1.54M$1.87M$9.69M$18.8M
Capital lease obligations$1.69M$1.54M$2.52M$1.43M$1.13M
Total liabilities$7.48M$8.44M$8.42M$41.3M$41.2M
Common stock$40K$40K$30K$10K$10K
Retained earnings-$-283.54M-$-251.39M-$-221.52M-$-189.78M-$-184.58M
Accumulated other comprehensive income (loss)$10K$60K$10K$0.00$0.00
Total equity$11.5M$26.3M$19.5M-$-35.78M-$-33.11M
Total investments$9.26M$22.3M$13.8M$0.00$0.00
Total debt$1.69M$1.87M$2.52M$26.4M$25.3M
Net debt-$-3.65M-$-6.7M-$-6.9M$26M$20.8M
Cash flow statement
20252024202320222021
Net income-$-32.15M-$-29.87M-$-28.3M-$-5.21M-$-16.38M
Depreciation and amortization$240K$900K$1.02M$970K$900K
Stock-based compensation$5.87M$6.07M$5.2M$2.42M$4.27M
Change in working capital-$-1.05M$750K-$-3.28M-$-1.69M$4.08M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.21M$2.16M-$-2.36M$2.31M$750K
Net cash provided by operating activities-$-25.27M-$-21.23M-$-20.27M-$-3.57M-$-6.58M
Investments in property, plant and equipment-$-1.1M-$-380K-$-1.02M-$-50K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$12.1M-$-8.13M-$-14.72M-$-50K$0.00
Common stock issued$9.89M$27.8M$39.7M$120K$140K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.89M$28.5M$44M-$-480K-$-270K
Net change in cash-$-3.23M-$-850K$9.02M-$-4.1M-$-6.86M
Cash at end of period$5.33M$8.56M$9.42M$400K$4.5M
Operating cash flow-$-25.27M-$-21.23M-$-20.27M-$-3.57M-$-6.58M
Capital expenditure-$-1.1M-$-380K-$-1.02M-$-50K$0.00
Free cash flow-$-26.37M-$-21.61M-$-21.3M-$-3.62M-$-6.58M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Genelux Corporation

        Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

        CEO
        Thomas D. Zindrick
        Employees
        26
        Beta
        0.57

        Explore

        Frequently asked questions

        What is the intrinsic value of Genelux Corporation (GNLX)?

        Genelux Corporation (GNLX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GNLX undervalued?

        GNLX trades at a price of $2.17 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.